RNA Therapeutics
TransCode Therapeutics Appoints Scientific Advisory Board Chair, Partners with Michigan State University to Advance RNA-Based Cancer Therapies
TransCode Therapeutics announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with Michigan State University to advance its RNA-based therapeutic pipeline, including lead candidate TTX-MC138.
Oncotelic Therapeutics Fills Critical Gaps in Cancer Treatment with RNA and Small-Molecule Therapies
Oncotelic Therapeutics is developing innovative RNA therapeutics and small-molecule drugs to address unmet needs in rare pediatric cancers and resistant solid tumors where traditional treatments have fallen short.
TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Trial of TTX-MC138
TransCode Therapeutics has successfully completed Phase 1a clinical trials for TTX-MC138, an RNA-based cancer treatment targeting metastatic disease, showing promising safety results and disease stabilization in nearly half of patients, advancing to Phase 2 evaluation.
Oncotelic Therapeutics Featured in Editorial Highlighting Innovative Cancer and Rare Disease Pipeline
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial underscores the company's growing prominence in developing RNA-based and immunotherapy treatments for aggressive cancers and pediatric rare diseases, positioning it for significant market growth.
MIT Researchers Develop AI Method to Enhance RNA Nanoparticle Design for Improved Therapeutics
MIT researchers have created an AI-driven approach to optimize RNA nanoparticle design, potentially revolutionizing the delivery of RNA vaccines and treatments while highlighting the growing commercial impact of quantum computing companies like D-Wave.
EnPlusOne Biosciences Aims to Revolutionize RNA Therapeutics with Enzymatic Synthesis
EnPlusOne Biosciences, under the leadership of CEO Clare Murray Ph.D., is pioneering an enzymatic approach to RNA synthesis, addressing the limitations of current methods and paving the way for scalable, pure, and environmentally friendly RNA therapeutics.
RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading RNAi researcher, to its Scientific Advisory Board, potentially strengthening the company's oncology research capabilities and RNA therapeutic development strategies.
TransCode Therapeutics Advances RNA Cancer Therapy, Reaches Milestone in Phase 1a Trial
TransCode Therapeutics has successfully dosed 15 patients in its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138, with early data showing promising target engagement and no significant toxicities.
TransCode Therapeutics Advances RNA Cancer Therapy in Phase 1a Trial, Shows Promising Early Results
TransCode Therapeutics reports encouraging progress in its Phase 1a trial of TTX-MC138, an RNA-based cancer therapy targeting microRNA-10b, with initial data suggesting potential effectiveness in treating metastatic tumors.
Silexion's Cancer Drug Shows Promise in Precision Oncology Market
Silexion Therapeutics demonstrates significant progress in KRAS-targeted cancer treatment with their RNAi therapeutic SIL-204, positioning the company as a notable player in the rapidly consolidating precision oncology market valued in billions.